Drug profile

The FDA adverse-event record for Bordetella Vaccine From Another Manufacturer

11 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Bordetella Vaccine From Another Manufacturer. See the species affected, top reactions, and outcomes below.

11
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
7
Lethargy (see also Central nervous system depression in Neurological) - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
11
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Bordetella Vaccine From Another Manufacturer

Administration Routes

UnknownNasalSubcutaneous

Species Affected

Dog 11

Most Affected Breeds

Retriever - Golden 2
Siberian Husky 1
Dachshund (unspecified) 1
Terrier - Bull - American Pit 1
Boxer (German Boxer) 1
Collie - Rough-haired 1
Mountain Dog - Bernese 1
Terrier - Boston 1
Bulldog - French 1
Pug 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 7
Vomiting 3
Hives (see also Skin) 3
Not eating 2
Anaphylaxis 2
Pale mucous membrane 2
Decreased appetite 2
Fever 2
Hypersensitivity reaction 2
Diarrhoea 1
Inappropriate defecation 1
Inappropriate urination 1

Outcome Breakdown

Ongoing
6 (54.5%)
Recovered/Normal
5 (45.5%)

Bordetella Vaccine From Another Manufacturer Adverse Event Insights

11 reports name Bordetella Vaccine From Another Manufacturer; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Bordetella Vaccine From Another Manufacturer. Administration routes: Unknown, Nasal, Subcutaneous.

By species: Dog (11 reports). By breed: Retriever - Golden (2), Siberian Husky (1), Dachshund (unspecified) (1).

Leading clinical signs: Lethargy (see also Central nervous system depression in Neurological) (7), Vomiting (3), Hives (see also Skin) (3), Not eating (2). Outcome, 11 coded reports: Ongoing leads at 54.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.